Slide 1: Proven Ability In Life Sciences
Proven Ability In Life Sciences February 15, 2024 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001. Mumbai – 400 051. Scrip co
Slide 2: Earnings Presentation Q3 FY24
SeQuent Scientific Limited Earnings Presentation Q3 FY24 February 2024
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 4: Sequent Scientific – At a glance
Sequent Scientific – At a glance India’s Only Largest 5 30+ USFDA approved API Animal Health company from Global R&D centres facility supplying Years of Animal Health APIs India Market Excellence 7* 9 100+ State of the art Strategic acquisitions Countries with marketing manufacturing facilities pres
Slide 5: Sequent Scientific – Q3 FY24 Earnings Release
Sequent Scientific – Q3 FY24 Earnings Release I am pleased to share that our transformation program to reshape our operations, optimize costs and enhance profitability has begun to deliver and reflect in the financials. EBITDA margin (pre-ESOP costs) for Q3FY24 stood at 9.2%, with EBITDA growing 15%
Slide 6: Q3 FY24: Key Highlights
Q3 FY24: Key Highlights • Pre-ESOP cost EBITDA growth of 15% q-o-q / 9% y-o-y • EBITDA margin pre-ESOP costs at 9.2%; expanded by 160 q-o-q / 180 bps y-o-y; on track to deliver double digit margins in Q4 Business Results • Revenue growth adjusted for discontinued business and Turkey currency account
Slide 7: Q3 FY24: Continuing margin expansion
Q3 FY24: Continuing margin expansion 4500 60.00% 9.2% 4000 7.6% 302 7.4% 263 50.00% 3500 277 3.5% 2.8% 45.1% 45.2% 42.1% 128 93 3000 41.5% 40.00% 39.5% 2500 30.00% 2000 3753 3667 3332 3460 3294 1500 20.00% 1000 10.00% 500 0 0.00% Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Revenue (INR mn) Gross Margin
Slide 8: Q3 FY24: Revenue Performance – by geography
Q3 FY24: Revenue Performance – by geography All values in ₹ Mn QnQ Gr% YoY Gr% YoY Gr% Revenue Distribution Q3 FY24 Q2 FY24 QnQ Gr% Q3 FY23 YoY Gr% 9M FY24 9M FY23 YoY Gr% (In cc) (In cc) (In cc) Formulations 2,510 2,532 (0.9%) 5.3% 2,591 (3.1%) 2.5% 7,520 7,456 0.9% 0.6% Europe 1,269 1,191 6.5% 6.8
Slide 9: Q3 and 9M FY24 Financials
Q3 and 9M FY24 Financials ~N ee S
Slide 10: Q3 and 9M FY24 Consolidated Financials
Q3 and 9M FY24 Consolidated Financials All values in ₹ Mn Q3 Q2 Q3 Grw Grw 9M 9M Grw Particulars Q3 CY vs Q3 LY FY24 FY24 FY23 QnQ % YoY % FY24 FY23 YoY % Revenue from Operations 3,294 3,460 3,753 -5% -12% 10,085 10,542 -4% • 310 bps of yoy Gross Material Consumption (1,806) (1,898) (2,174) (5,652)
Slide 11: For details, feel free to contact
For details, feel free to contact: Phillip Trott Abhishek Singhal Nachiket Kale Company Secretary Investor Relations Consultant Investor Relations Advisor +91 22 4111 4777 abhishek.s@sequent.in +91 9920940808 investorrelations@sequent.in nachiket.kale@linkintime.co.in Registered Office: 301/A, ‘Dost
Slide 12: Thank You
Thank You 11